Peace K E, Carter W H
Biopharmaceutical Research Consultants, Inc., Ann Arbor, Michigan 48105.
J Biopharm Stat. 1993 Mar;3(1):129-40. doi: 10.1080/10543409308835053.
Differential exposure to study medications in long-term studies of some cardiovascular compounds complicates analyses, particularly the usual intention-to-treat analyses and inferences therefrom of the data collected. Analysis methods that incorporate exposure are developed, presented, and illustrated by applying them to primary response data from a long-term, placebo-controlled, ancillary trial of gemfibrozil. The analysis methods address the extent to which end-points are correlated with the actual use of the compound rather than the extent to which end-points are correlated with the random assignment to double-blind study medications.
在某些心血管化合物的长期研究中,对研究药物的差异暴露使分析变得复杂,尤其是常规的意向性分析以及由此对所收集数据进行的推断。本文开发、展示并通过将其应用于吉非贝齐的一项长期、安慰剂对照、辅助试验的主要反应数据来说明纳入暴露因素的分析方法。这些分析方法关注的是终点与化合物实际使用的相关程度,而非终点与双盲研究药物随机分配的相关程度。